Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here

Real world study finds Pfizer-BioNTech Covid-19 vaccine to be 92% effective

16 Apr 2021 (Last Updated April 16th, 2021 08:17)

16 April

Shane Oliver, an economist, retweeted an article on a real-world study of more than one million people in Israel, and the effect of the Pfizer-BioNTech Covid-19 vaccine (BNT162b2 mRNA) in a nationwide mass vaccination settling.

The study revealed vaccine effectiveness against the coronavirus infection to be 92%, seven days after being administered the second dose.

Estimated effectiveness in preventing death from Covid-19 was 72% for 14 days through 20 after the first dose.

Effectiveness in specific subgroups of the population assessed for documented infection and symptomatic Covid-19 was consistent across age groups, with slightly lower effectiveness in people with other multiple co-existing conditions.

The study confirmed that the vaccine is effective for a wide range of Covid-19-related outcomes, a finding that is consistent with the results of the randomised trial.

Read more